Cruxium
25-05-2006, 22:16
*An article delivered anonymously to several media sources.*
LifeWyze announced today that it had made an agreement with the German pharmaceutical research company, TeGenero Immuno Theraputics, to purchase all research pertaining to TGN1412.
TGN1412 was originally designed as an immunomodulatory drug to treat B cell chronic lymphocytic leukemia and rheumatoid arthritis. However, on March 13, 2006, the initial test upon six human subjects caused four to suffer major organ failure throughout their bodies. When questioned upon the purchase of the TGN1412 research, a LifeWyze BioTech representative had this to say;
"It is the hope of LifeWyze BioTech to refine this drug in order for it to fulfill its' intended purpose, the treatment of B-CLL and arthritis. There are also discussions regarding other possible applications of TGN1412."
It is unclear how much LifeWyze has paid for this research, though it is unlikely to be a large amount as TeGenero is currently in extreme financial difficulty as the human test subjects are engaged in a legal battle with the company, which was only insured for two million GBP in the test. Rumours abound regarding the meaning of 'other possible applications' and may add to the list of reasons behind the League of Nations investigation into LifeWyze BioTech business practices.
Hope exists, however, that TGN1412 will be refined by LifeWyze BioTech, whose annual profits were in excess of $250bn last year and has seen astronomical growth of its' various medical facilities. LifeWyze BioTech reached international proportions with the development of its' privatized hospitals.
LifeWyze announced today that it had made an agreement with the German pharmaceutical research company, TeGenero Immuno Theraputics, to purchase all research pertaining to TGN1412.
TGN1412 was originally designed as an immunomodulatory drug to treat B cell chronic lymphocytic leukemia and rheumatoid arthritis. However, on March 13, 2006, the initial test upon six human subjects caused four to suffer major organ failure throughout their bodies. When questioned upon the purchase of the TGN1412 research, a LifeWyze BioTech representative had this to say;
"It is the hope of LifeWyze BioTech to refine this drug in order for it to fulfill its' intended purpose, the treatment of B-CLL and arthritis. There are also discussions regarding other possible applications of TGN1412."
It is unclear how much LifeWyze has paid for this research, though it is unlikely to be a large amount as TeGenero is currently in extreme financial difficulty as the human test subjects are engaged in a legal battle with the company, which was only insured for two million GBP in the test. Rumours abound regarding the meaning of 'other possible applications' and may add to the list of reasons behind the League of Nations investigation into LifeWyze BioTech business practices.
Hope exists, however, that TGN1412 will be refined by LifeWyze BioTech, whose annual profits were in excess of $250bn last year and has seen astronomical growth of its' various medical facilities. LifeWyze BioTech reached international proportions with the development of its' privatized hospitals.